UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 44,370 Shares of Elanco Animal Health Incorporated (NYSE:ELAN)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC decreased its holdings in shares of Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 2.9% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,510,447 shares of the company's stock after selling 44,370 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 0.31% of Elanco Animal Health worth $22,188,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently modified their holdings of the company. Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of Elanco Animal Health by 1.9% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 107,683 shares of the company's stock valued at $1,582,000 after buying an additional 2,051 shares during the last quarter. Freedom Investment Management Inc. grew its holdings in shares of Elanco Animal Health by 26.2% during the third quarter. Freedom Investment Management Inc. now owns 19,021 shares of the company's stock valued at $279,000 after purchasing an additional 3,952 shares during the last quarter. BNP Paribas Financial Markets raised its position in shares of Elanco Animal Health by 2,453.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 260,325 shares of the company's stock worth $3,824,000 after purchasing an additional 250,129 shares during the period. The Manufacturers Life Insurance Company lifted its holdings in shares of Elanco Animal Health by 6.6% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 6,385,467 shares of the company's stock worth $93,803,000 after purchasing an additional 394,921 shares during the last quarter. Finally, Qsemble Capital Management LP acquired a new position in Elanco Animal Health during the 3rd quarter valued at approximately $264,000. 97.48% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on ELAN. Morgan Stanley lowered Elanco Animal Health from an "overweight" rating to an "equal weight" rating and dropped their target price for the stock from $17.00 to $15.00 in a research report on Thursday, September 19th. Barclays lifted their price objective on shares of Elanco Animal Health from $19.00 to $20.00 and gave the company an "overweight" rating in a research report on Friday, November 8th. Leerink Partnrs upgraded shares of Elanco Animal Health to a "hold" rating in a research report on Monday. Leerink Partners initiated coverage on Elanco Animal Health in a report on Monday. They set a "market perform" rating and a $14.00 price target on the stock. Finally, Stifel Nicolaus reiterated a "buy" rating and set a $20.00 price objective on shares of Elanco Animal Health in a research report on Thursday, September 19th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and four have issued a buy rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus target price of $16.75.

Elanco Animal Health Stock Up 3.1 %

Elanco Animal Health stock traded up $0.38 during mid-day trading on Friday, hitting $12.50. The company's stock had a trading volume of 4,585,158 shares, compared to its average volume of 4,772,569. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.55 and a quick ratio of 1.31. Elanco Animal Health Incorporated has a 52-week low of $11.40 and a 52-week high of $18.80. The firm's 50 day moving average is $13.46 and its 200 day moving average is $14.52. The company has a market cap of $6.18 billion, a PE ratio of 30.25, a price-to-earnings-growth ratio of 2.02 and a beta of 1.41.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last posted its quarterly earnings results on Thursday, November 7th. The company reported $0.13 EPS for the quarter, topping the consensus estimate of $0.12 by $0.01. The business had revenue of $1.03 billion during the quarter, compared to analysts' expectations of $1.04 billion. Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. The firm's quarterly revenue was down 3.6% compared to the same quarter last year. During the same period last year, the company posted $0.18 earnings per share. On average, analysts anticipate that Elanco Animal Health Incorporated will post 0.92 earnings per share for the current year.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.